- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Patrick Courneya, MD, Discusses Patrick the Current Models Redesigning the Healthcare System
Patrick Courneya, MD, CHIE, health plan medical director, HealthPartners, Inc, says that his organization sees a wide variety of models in Minnesota.
Patrick Courneya, MD, CHIE, health plan medical director, HealthPartners, Inc, says that his organization sees a wide variety of models in Minnesota. The spectrum of models include single specialty primary care groups, who deliver the highest quality of care based on measures within the marketplace, to large multispecialty groups who compete effectively within the triple aim.
Dr Courneya says care delivery systems often provide services to patients in high population areas, as well as those in lower-populated areas. The challenges and solutions for each population are vastly different. “As we as a health plan work with those different organizations, we need to understand in detail about their world, their tools, their capabilities, and their aspirations as care delivery systems and as communities,” said Dr Courneya.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
